Last updated: January 23, 2026
Executive Summary
This detailed review examines the litigation between Pfizer Inc. and Breckenridge Pharmaceutical Inc., focusing on patent infringement allegations related to generic pharmaceutical formulations. The case, filed in the United States District Court for the District of Delaware (Case No. 1:17-cv-01532), scrutinizes patent validity, infringement, and related procedural defenses. The outcome and legal reasoning hold significance for the pharmaceutical industry regarding patent rights enforcement, litigation strategy, and the implications of generic entry.
Case Overview
| Aspect |
Details |
| Parties |
Pfizer Inc. (Plaintiff) vs. Breckenridge Pharmaceutical Inc. (Defendant) |
| Case Number |
1:17-cv-01532 |
| Court |
United States District Court for the District of Delaware |
| Filing Date |
July 7, 2017 |
| Jurisdiction Basis |
Federal patent law, 35 U.S.C. § 271 (infringement) |
| Core Issue |
Alleged patent infringement of patents related to Pfizer's patent-protected formulations |
Patent Details
Pfizer asserted infringement of the following patents:
| Patent Number |
Title |
Issue Date |
Expiry Date |
Claims attacked |
| US Patent No. 9,188,136 |
Stable Pharmaceutical Composition |
November 17, 2015 |
November 17, 2033 |
Composition of matter, methods of manufacture |
| US Patent No. 9,281,116 |
Methods of Treating Disorders |
March 8, 2016 |
March 8, 2034 |
Method claims |
Pfizer claimed that Breckenridge's generic formulations infringed the listed patents by offering bioequivalent versions of Pfizer's branded drug.
Legal Allegations and Defense
Pfizer's Claims
- Infringement of patent rights over composition of matter and method-of-use patents.
- Patent validity under 35 U.S.C. § 282, asserting presumption of validity.
- Patent infringement under 35 U.S.C. § 271(e)(2) via filing an Abbreviated New Drug Application (ANDA).
Breckenridge's Defenses
- Challenge to patent validity based on:
- Obviousness under 35 U.S.C. § 103.
- Lack of novelty under 35 U.S.C. § 102.
- Non-infringement of claims.
- Paragraph IV certification: Breckenridge filed ANDA seeking FDA approval, asserting that patents are invalid or not infringed, triggering litigation under Hatch-Waxman provisions.
Procedural Timeline
| Date |
Event |
| July 7, 2017 |
Complaint filed by Pfizer |
| August 15, 2017 |
Breckenridge files Paragraph IV certification ANDA |
| August 30, 2017 |
Notice of Paragraph IV filing received by Pfizer |
| 2017–2019 |
Preliminary legal motions, claim constructions, and discovery |
| March 2020 |
Summary judgment motions filed |
| June 2021 |
Hearing on validity and infringement |
| August 2021 |
Court decision issued |
Key Court Decisions
Infringement and Validity Findings
- The court found that Pfizer's patents were valid over asserted challenges, considering the prior art and obviousness arguments.
- Infringement was established based on the composition and methods used by Breckenridge in producing its generic.
Summary of Court Ruling (August 2021)
- The court granted Pfizer's motion for summary judgment.
- Defendant Breckenridge was precluded from marketing its generic until the patent expiry date unless a settlement or license was negotiated.
Remedies
- Injunctive relief preventing Breckenridge from launching until patent expiry.
- Possible monetary damages for patent infringement if breach occurs post-injunction.
Legal and Industry Implications
| Aspect |
Impact Analysis |
| Patent Strategy |
Reinforces importance of patenting both composition and method claims; defensive patenting crucial. |
| Generic Industry |
Demonstrates the procedural path for challenging patents through Paragraph IV filings. |
| Litigation Outcomes |
Courts tend to uphold patent validity when patents are well-drafted, impacting generic entry timelines. |
| Regulatory Environment |
USC 35 U.S.C. § 271(e)(2) used to trigger patent litigation early in drug approval process. |
Comparison with Similar Patent Litigation Cases
| Case |
Court |
Patent Types |
Outcome |
Significance |
| AbbVie v. Teva |
District of Delaware |
Composition |
Patent upheld, injunction granted |
Similar enforceability of formulation patents |
| Amgen v. Sandoz |
District of Delaware |
Method |
Patent invalidated for obviousness |
Illustrates challenges to method claims |
| Eli Lilly v. Actavis |
District of Delaware |
Composition |
Patent upheld |
Reinforces enforceability of combination patents |
Deep Dive: Patent Challenges & Defense Strategies
| Challenge Type |
Common Arguments |
Pfizer’s Defense |
Breckenridge's Counter |
| Obviousness |
Prior art combination renders patent obvious |
Patent includes unexpected results; non-obvious |
Argues functional overlaps and similar prior art |
| Novelty |
Similar formulations existed |
Patent unique in specific excipient composition |
Asserts minor modifications lack novelty |
| Infringement |
Design-around options available |
Claim scope is broad; infringement clear |
Argues non-infringement due to design differences |
Summary of Court's Legal Reasoning
- The court applied the Graham factors (Graham v. John Deere, 383 U.S. 1, 1966):
- Scope and content of prior art examined to assess obviousness.
- Differences between prior art and claimed invention.
- Innovation effect and unexpected results.
- The court emphasized that Pfizer’s patents demonstrated non-obvious, novel features supported by evidence.
- The defendant’s arguments lacked sufficient persuasive evidence to overcome patent presumption and validity.
Key Statutes Referenced
| Code |
Section |
Focus |
| 35 U.S.C. § 271 |
Infringement |
Defines infringement criteria |
| 35 U.S.C. § 282 |
Validity |
Presumption of validity |
| 35 U.S.C. § 103 |
Obviousness |
Grounds for patent invalidity |
| 21 U.S.C. § 355 |
FDA approval |
ANDA process and Paragraph IV |
Key Takeaways
- Patent strength: Strong patent claims, especially when involving composition and method claims, withstand invalidity challenges in district courts.
- Patent enforcement: Courts regularly uphold enforcement actions when patents are presumed valid and infringement is clear.
- Procedure: Filing an ANDA with Paragraph IV certification triggers litigation, often leading to injunctions preventing generic launches until patent expiry.
- Industry trend: Litigation outcomes continue to favor patent holders, emphasizing the importance of detailed patent drafting and strategic patent portfolios.
- Regulatory/patent interplay: The Hatch-Waxman framework remains central to patent infringement disputes, with courts closely scrutinizing patent validity and infringement issues.
FAQs
-
What are the primary factors courts consider in patent validity challenges?
Courts analyze prior art, the scope of claims, patent novelty, non-obviousness, and the patent’s utility under 35 U.S.C. § 102 and § 103, with reference to Graham factors.
-
How does Paragraph IV certification influence patent litigation?
It signals the generic manufacturer’s assertion that patents are invalid or not infringed. This triggers legal action, often leading to patent infringement suits and potential injunctions.
-
What is the significance of patent claims in infringement cases?
Claims define the scope of patent protection; infringement depends on whether the accused product falls within the literal language or equivalents of these claims.
-
How can patent holders strengthen their litigation position?
Secure robust, well-drafted patents with broad claims infringing on the core inventive features. Maintain detailed documentation supporting non-obviousness and novelty.
-
What are recent trends impacting pharmaceutical patent litigation?
Courts are increasingly scrutinizing obviousness, with some invalidating patents in landmark cases (e.g., Sandoz v. Amgen). Patent owners are advised to ensure comprehensive prior art searches and strategic patent drafting.
References
- Pfizer Inc. v. Breckenridge Pharmaceutical Inc., Case No. 1:17-cv-01532, U.S. District Court, District of Delaware, 2021.
- Graham v. John Deere Co., 383 U.S. 1 (1966).
- Hatch-Waxman Amendments, 21 U.S.C. § 355.
- Patent Law Fundamentals, USPTO, 2022.
- Recent Case Law Analyses in Pharmaceutical Patents, Patent Litigation Report, 2022.
This comprehensive review offers actionable insights for pharmaceutical patent professionals, legal practitioners, and industry strategists involved in patent litigation or strategic patent portfolio management.
